Oncology

Latest News

FDA Approved

Repotrectinib Approved for Use in NTRK-Positive Solid Tumors

By Julia Bonavitacola

June 14th 2024

Neurotrophic tyrosine receptor kinase (NTRK)–positive locally advanced or metastatic solid tumors can now be treated with the first FDA-approved treatment option.

Human kidney cross section on scientific background | Crystal light - stock.adobe.com

Treatment-Free Survival Extended With Nivolumab/Cabozantinib in Advanced Renal Cell Carcinoma

By Kyle Doherty

June 13th 2024

What We’re Reading: Federal Judge Blocks Florida Ban on Gender-Affirming Care; NASEM Releases Definition for Long COVID; NIH Pilot Fails to Diversify Cancer Research

What We’re Reading: Florida Ban on Gender-Affirming Care Blocked; Definition for Long COVID; NIH Pilot Fails to Diversify Cancer Research

June 12th 2024

Antibody drug conjugate in blue | huenstructurebio.com - stock.adobe.com

Antibody Drug Conjugates Show Promise in Biomarker, Prognostic Outcomes in Oncology Care

By Pearl Steinzor

June 5th 2024

Enhertu packaging | Image credit: AstraZeneca

Wave of Antibody-Drug Conjugates Poised to Change Treatment Paradigms Across Multiple Cancers

May 29th 2024

Continuing Medical Education

Continuing Medical Education

More News

May 10th 2012

Visit Duration for Outpatient Physician Office Visits Among Patients With Cancer

Gery P. Guy Jr, PhD, MPH Lisa C. Richardson, MD, MPH

Higher use of performance-based payment mechanisms and capitated arrangements is associated with a decrease in the amount of time physicians spend with patients with cancer.

May 10th 2012

Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 US Claims Data Analysis

Martin L. Raborn, MPharm, MBA Elise M. Pelletier, MS Daniel B. Smith, MA Carolina M. Reyes, PhD

Out-of-pocket payments differ widely among oral oncolytic options. As cost for therapy becomes a greater part of treatment decisions, an understanding of patient out-of-pocket cost will be critical in informing choices.

May 10th 2012

Effect of Insurance Status on the Stage of Breast and Colorectal Cancers in a Safety-Net Hospital

Daniel T. Farkas, MD Arieh Greenbaum, BA Vinay Singhal, MD John M. Cosgrove, MD

In a safety-net hospital, patients with Medicaid have rates of advanced-stage cancer similar to those patients with other types of insurance; however, patients with no insurance have significantly higher rates of advanced disease.

May 10th 2012

US Payer Perspectives on Evidence for Formulary Decision Making

Anthony Wang, MPH Ronald J. Halbert, MPH, MD Tiffany Baerwaldt, BA Robert J. Nordyke, MS, PhD

To improve formulary design processes and support payers in providing more effective healthcare, policy makers should consider involving commercial payers in the development of comparative effectiveness research and creation of research and treatment guidelines.

May 10th 2012

Evidence Gaps in Advanced Cancer Care: Community-Based Clinicians' Perspectives and Priorities for CER

Sarah J. Lowry, MPH Elizabeth T. Loggers, MD, PhD Erin J. A. Bowles, MPH Edward H. Wagner, MD, MPH

Comparative effectiveness research and pragmatic clinical trials are valued methods to address the limitations of traditional randomized trials, answer questions of cost-effectiveness or noninferiority, and inform data-driven dialogue and decision making by stakeholders.

May 10th 2012

Treating ALK-Positive Lung Cancer in the Weeks After the FDA Approval of Crizotinib

Nathan A. Pennell, MD, PhD

As physicians enter a new world of therapies for molecularly defined lung cancer, it will be critical for hospitals, drug companies, and insurance companies to work out the interplay of molecular testing and coverage for expensive therapies that are effective but only in smaller, defined groups of patients.

May 10th 2012

John V. Cox, DO, MBA, FACP A. Mark Fendrick, MD

Journal of Oncology Practice (JOP) and The American Journal of Managed Care (AJMC) join efforts to highlight work focusing on issues affecting payers and providers.

May 9th 2012

Infused Chemotherapy Use in the Elderly After Patent Expiration

Rena M. Conti, PhD Meredith B. Rosenthal, PhD Blase N. Polite, MD Peter B. Bach, MD, MAPP Ya-chen Tina Shih, PhD

As calls for improving the quality and cost efficiency of oncology increase, future empirical work is needed to examine the responsiveness of oncologists' treatment decision making to incentives among patients of all ages and insurance types.

May 9th 2012

Cost-Effectiveness Analysis of SBRT Versus IMRT: An Emerging Initial Radiation Treatment Option for Organ-Confined Prostate Cancer

Joseph C. Hodges, MD, MBA Yair Lotan, MD Thomas P. Boike, MD Rhonda Benton, BS, CMC Alyson Barrier, BBA Robert D. Timmerman, MD

Stereotactic body radiation therapy for low- to intermediate-risk prostate cancer has potential cost savings and may improve access to radiation, increase convenience, and boost quality of life.

May 9th 2012

Impact of Payment Reform on Chemotherapy at the End of Life

Carrie H. Colla, PhD Nancy E. Morden, MD, MPH Jonathan S. Skinner, PhD J. Russell Hoverman, MD, PhD Ellen Meara, PhD

Payment reform may be used to better align appropriate financial incentives with better quality of care.

May 8th 2012

Development of a Multidisciplinary, Multicampus Subspecialty Practice in Endocrine Cancers

Keith C. Bible, MD, PhD Robert C. Smallridge, MD John C. Morris, MD Julian R. Molina, MD Vera J. Suman, PhD John A. Copland, PhD Joseph Rubin, MD Michael E. Menefee, MD Kostandinos Sideras, MD

The development of subspecialty tumor groups for uncommon malignancies represents an effective approach to building experience, increasing patient volumes and referrals, and fostering development of increased therapeutic options and clinical trials for patients afflicted with otherwise historically neglected cancers.

May 7th 2012

Focus on Oncology

There have been many research advancements in oncology over the past several weeks, including a new blood test designed to predict the onset of breast cancer; new control techniques for oncology payer management; and the creation of a new electronic tool for oncology nurses to improve patient outcomes.

April 24th 2012

Services Match Patients With Clinical Trials

April 23rd 2012

Key Takeaways from the Academy of Managed Care Pharmacy 24th Annual Meeting

The American Journal of Managed Care team had the opportunity to attend the Academy of Managed Care Pharmacy's 24th Annual Meeting in San Francisco this past week. Here are some of the key takeaways from the very informative sessions.

April 19th 2012

VIDEO: Mark Zitter, MBA, Speaks About the Importance of Oncology Pathways

In this video, Mark Zitter, MBA, CEO of the Zitter Group, speaks about how oncology pathways are affecting drug use.

April 18th 2012

Managed Care and Oncology Pharmacy Management: Focus on Multiple Myeloma

Wednesday morning at the Academy of Managed Care Pharmacy 24th Annual Meeting featured a satellite symposium that focused on the evolving role of managed care and oncology pharmacy management. The presentations by distinguished faculty reviewed current evidence-based data to enable decision making based on indicators of treatment outcomes for multiple myeloma; demonstrated the use of comparative effectiveness research (CER) as a decision support tool; and evaluated innovative pharmacy benefit models and specialty management services.

April 13th 2012

Cancer Care Grand Rounds

April 10th 2012

FDA Makes Plans to Correct Cancer Drug Shortages in the U.S.

April 5th 2012

Drug Spending Levels Off, But Not For The Usual Reasons

April 4th 2012

The Cost of Cancer Care

March 19th 2012

Technologies Behind Biomarker Discovery and Development

Kim L. Farina, PhD

Metabolomics, Proteomics, and Epigenetics

March 16th 2012

The Truth About Electronic Health Records

Why Oncologists Must Tailor Clinical Features to Their Needs

March 16th 2012

The Great Biomarker Chase

Laura Mortkowitz

Promise and Pitfalls Along the Path to Personalized Care

March 16th 2012

The 4 Pillars: Foundation for Care

The Duke Cancer Institute

March 16th 2012

To help oncology providers better understand drug mechanisms of action, and the economic implications of their use.

March 16th 2012

Latest in Literature

Review of the most recent evidence-based literature discussing breast, colorectal, lung, and ovarian cancers, in addition to melanoma and multiple myeloma.

March 16th 2012

The Economics of Cancer Care in the United States

Kim L. Farina, PhD

How Much Do We Spend and How Can We Spend It Better?

March 12th 2012

Putting Value Into Practice

A. Mark Fendrick, MD Jonas de Souza, MD

Insights Into Value-Based Insurance Design in Oncology

March 12th 2012

Trying Something New: Episode Payments for Cancer Therapy

Lee N. Newcomer, MD, MHA

Radical Changes in Payment Incentives and Elimination of Low-Value Care

March 12th 2012

Payer Management of Oncology Gets Serious

Michael Synder, BA Lee Goldberg, MBA Tracey Ryan, M.Eng

Health Plans Continue to Seek Methods to Curtail Cancer Costs

...

170 171 172 173 174 175 176 177 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions